secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001851734-23-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen completes Pherin acquisition, reports Q3 net loss $9.8M; PH94B Phase 3 adjusted
--------------------------------------------------------------------------------

- Acquired Pherin Pharmaceuticals; eliminated all future royalty obligations on PH94B and PH10; added three new pherine candidates.
- PH94B Phase 3 plan: PALISADE-1 had unexpected results; preparing FDA meeting; considering multiple-administration LSAS study.
- PH10 received FDA Fast Track designation for major depressive disorder; Phase 1 trial underway; Phase 2A AjDA topline results expected Q1 2023.
- Q3 net loss $9.8M vs $10.7M YoY; R&D decreased $0.9M to $6.9M; cash $25.0M at Dec 31, 2022.
- Shares outstanding 219.3M, including ~12.4M shares issued for Pherin acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000185173423000037/0001851734-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000185173423000037/vtgn20230207_8k.htm
  HTML page:      https://secwatch.observer/filing/0001851734-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer